ArticleBMC nephrology2025
A case report of metastatic renal cell carcinoma and ANCA associated vasculitis.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal Cell Carcinoma (RCC) may uncommonly present concurrently with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Most instances are malignancies discovered incidentally during the work up after a diagnosis of AAV; however, the significant overlap between these disorders potentially suggests a more complex pathophysiology. We present the case of a 53-year-old gentleman who was diagnosed with metastatic RCC who later developed rapidly progressive kidney failure and a vasculitic rash after commencement of a tyrosine kinase inhibitor and was ultimately diagnosed with subsequent concurrent AAV. Treatment included suspending immunotherapy, glucocorticoids, and rituximab induction. This case highlights the unique scenario of concurrent RCC and AAV, including the potential pathophysiology of a pro-inflammatory milieu created in the setting of RCC which permits AAV. It also outlines the complexity of treating an autoimmune disorder in the setting of an active cancer requiring immunotherapy and the difficult balance between these two treatment paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.